Search result from the Trials Tracker
Study details
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
- Trials Tracker ID
- TT001956
- Age range
- 12 years and older
- Trial status
- Recruitment complete
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Study results summary
Vertex made the decision to terminate study VX17-659-105 when the entire VX-659 programme was halted in favour of a more effective programme in the same patient population.
- Trials Tracker ID
- TT001951
- Age range
- 12 years and older
- Trial status
- Study discontinued early
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Study results summary
Kaftrio treatment was generally safe and effective for people with cystic fibrosis ages 12+ with Phe508del-minimal function genotypes for whom previous CFTR modulator treatments were not effective. These results support Kaftrio as a treatment for people with these gene variants.
- Trials Tracker ID
- TT001941
- Age range
- 12 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
The study is a randomized, double-blind, placebo-controlled, study that will be conducted at multiple centers in subjects with Cystic Fibrosis (CF) who are homozygous for the F508del mutation.
- Trials Tracker ID
- TT001936
- Age range
- 18 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
This study tests the effects of an experimental drug PC945 in people with cystic fibrosis whose lungs are infected by the fungus Aspergillus fumigatus. PC945 may be useful in treating patients infected with Aspergillus fumigatus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will continue to be treated with their usual cystic fibrosis treatment and will also receive PC945. The amount of fungus in the patients' phlegm will be measured over the course of the study. The study will take place at multiple sites in...
Study updates
Four people were recruited onto the study and one person withdrew when the study was temporarily paused. The study was then terminated early as a result of the COVID-19 pandemic.
- Trials Tracker ID
- TT001926
- Age range
- 18 years and older
- Trial status
- Study discontinued early
- Therapeutic approach
- Anti-Infective
Search result from the Trials Tracker
This trial has been archived
Study details
Few people with CF have normal blood glucose control and these glucose abnormalities eventually progress to cystic fibrosis-related diabetes (CFRD), the most common complication of CF. The combination of diabetes and CF leads to increased morbidity and a six-fold increase in mortality. People with CF are encouraged to consume a high calorie diet to maintain weight. This typically means eating food and drinks that are often high in fat and/or sugar. For people with CF who also need to control their blood glucose levels, high sugar intake can make this difficult. There is limited evidence to guide dietary therapy for...
- Trials Tracker ID
- TT001921
- Age range
- Between 11 and 30 years
- Length of participation
- 4 months
- Trial status
- Closed with results
- Therapeutic approach
- Nutritional-GI
Our Activity Unlimited programme aims to help everyone with cystic fibrosis (CF) take control of their health with sport, exercise and physiotherapy.
Search result from the Trials Tracker
This trial has been archived
Study details
Lung Clearance Index (LCI) measured by multiple breath washout (MBW) has been shown to be a sensitive and non-invasive method of detecting early airways disease in infants with cystic fibrosis (CF). An abnormal measurement at a young age has been shown to track into later life, and could identify children that require more aggressive treatment earlier on. Currently however there is a lack of multi-centre data and of suitable scalable methodologies that can be used outside of highly specialised settings. This is a multi-centre longitudinal observational study of this measurement, LCI, in children younger than 3 years with CF, with...
- Trials Tracker ID
- TT001916
- Age range
- Under 2 years
- Trial status
- Closed with results
- Therapeutic approach
- Other
Search result from the Trials Tracker
Study details
CF is caused by decreased quantity and/or function of the Cystic Fibrosis transmembrane conductance protein regulator (CFTR) protein due to mutations in the gene that codes for the CFTR protein. The CFTR protein regulates salt and water absorption and secretion and pH balance in sweat glands and multiple organs, including the lungs, pancreas, and other gastrointestinal organs. The most common disease-causing CFTR mutation is F508del and subjects can either have two copies of the gene, known as homozygous, or one copy, known as heterozygous. Therapies targeted at improving the function of the protein which is formed as a result of...
- Trials Tracker ID
- TT001906
- Age range
- 12 years and older
- Length of participation
- 24 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
